Further Agreement with Eli Li

RNS Number : 7733Y

Physiomics PLC

14 July 2008

 



Physiomics plc

The Magdalen Centre

The Oxford Science Park
Robert Robinson Avenue
Oxford

OX4 4GA
UK

Tel [phone]

Fax [phone]

14 July 2008            

Physiomics plc ('Physiomics' or 'the Company')

Physiomics Technology in continued and expanded support of Lilly's Oncology Programs 

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology.  Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year of a specific project studying cancer cellular processes for drugs targeting the cell cycle (the natural process of controlling cell proliferation).

The overall aim of the first new project is to provide a rationale for the identification of patient subpopulations that could benefit from an undisclosed target inhibitor (drug candidate). Physiomics' role is to provide this rationale, based on identifying and illustrating the mechanisms underlying the response of cells with different genetic backgrounds to this class of inhibitors given alone and in combination with other drugs. 

For the second project, a customised model will be produced which integrates various biomarkers currently being investigated by Lilly as functional readouts for proprietary undisclosed target (distinct from the above-mentioned target) inhibitors. The model will provide a rational mechanistic understanding of the involvement of these biomarkers in the functional response to the inhibitors. In so doing, the model will be used to select optimal dosing regimes for the drugs either alone or in combination with other drugs.

Dr Christophe Chassagnole, COO of Physiomics, said:

'Clearly we are very pleased to be able to continue and expand our collaboration with Lilly following the satisfactory completion of a preliminary study designed to evaluate the technology and the team.  The needs of Lilly's discovery and development teams are very well matched to Physiomics's key expertise and capabilities in the challenging area of oncology. This is a vote of confidence in our team and our ability to apply a systems biology approach to the pharma R&D processe.'

For further information:

Physiomics plc                                                         [phone]

Dr Christophe Chassagnole, COO 

E-mail: [e-mail]

Grant Thornton UK LLP                                            [phone]

Colin Aaronson, Philip Secrett 

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates¹ show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

AGRBGGDRSGBGGIG